Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial

Thazhath, Sony S.; Wu, Tongzhi; Bound, Michelle J.; Checklin, Helen; Standfield, Scott; Jones, Karen L.; Horowitz, Michael; Rayner, Christopher K.

doi:10.3945/ajcn.115.117440

Cited by 105 publications

(83 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is in accordance with several other human studies also not observing effects of resveratrol supplementation on fasting lipid and glucose concentrations [3]. Further, a study on type 2 diabetic individuals did not find an effect on postprandial glucose concentrations [4]. Nevertheless, trans -resveratrol might affect other parameters related to cardiovascular health, such as vascular endothelial dysfunction.…”

Section: Introductionsupporting

confidence: 91%

Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants

Made

Mensink

2017

Nutrients

View full text Add to dashboard Cite

Studies on the effects of the long-term intake of trans-resveratrol on vascular function are conflicting. In addition, postprandial effects of long-term trans-resveratrol intake on endothelial function are not known. We therefore supplemented 45 overweight and slightly obese volunteers (25 men and 20 women) with a mean (±SD) age of 61 ± 7 years and body mass index of 28.3 ± 3.2 kg/m2 in random order trans-resveratrol (2 × 75 mg/day) or placebo capsules for 4 weeks, separated by a washout period of at least 4 weeks. At the end of each intervention period, brachial artery flow-mediated vasodilation (FMD) was measured before and after meal consumption. Plasma biomarkers for endothelial function, inflammation, and glucose and lipid metabolism were also determined. Compared with the placebo, trans-resveratrol did not affect fasting FMD (2.9 ± 1.4% vs. 3.0 ± 1.9%; p = 0.69). After the postprandial test, changes in FMD (−0.7 ± 2.3% vs. 0.2 ± 2.6%; p = 0.13) were also not significantly different. Postprandial changes in biomarkers were also comparable. In conclusion, for overweight and slightly obese volunteers, a daily intake of 150 mg of trans-resveratrol for 4 weeks does not change plasma biomarkers of endothelial function or inflammation in the fasting state or postprandial phase.

show abstract

Section: Introductionsupporting

confidence: 91%

Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants

Made

Mensink

2017

Nutrients

View full text Add to dashboard Cite

show abstract

“…On the other hand, in patients with metabolic syndrome, RSV supplementation did not have any effect on systolic and diastolic blood pressure [35,36]. Furthermore, in a recent randomized trial in type II diabetes patients, ingestion of 500mg/day of RSV for 5 weeks failed to show any beneficial effects [37]. Majority of clinical trials were centered on the therapeutic effects of RSV supplementation, whereas studies based on preventive approaches are still lacking.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity

et al. 2017

View full text Add to dashboard Cite

Resveratrol (RSV), a polyphenolic compound and naturally occurring phytoalexin, has been reported to exert cardio-protective effects in several animal studies. However, the outcome of initial clinical trials with RSV was less effective compared to pre-clinical studies. Therefore, RSV treatment protocols need to be optimized. In this study we evaluated prophylactic versus therapeutic effect of resveratrol (RSV) in mitigating doxorubicin (Dox)-induced cardiac toxicity in rats. To investigate prophylactic effects, RSV was supplemented for 2 weeks along with Dox administration. After 2 weeks, Dox treatment was stopped and RSV was continued for another 4 weeks. To study therapeutic effects, RSV treatment was initiated after 2 weeks of Dox administration and continued for 4 weeks. Both prophylactic and therapeutic use of RSV mitigated Dox induced deterioration of cardiac function as assessed by echocardiography. Also RSV treatment (prophylactic and therapeutic) prevented Dox induced myocardial damage as measured by cardiac enzymes (LDH and CK-MB) in serum. Which was associated with decrease in Dox induced myocardial apoptosis and fibrosis. Interestingly our study also reveals that prophylactic use of RSV was more effective than its therapeutic use in mitigating Dox induced apoptosis and fibrosis in the myocardium. Therefore, prophylactic use of resveratrol may be projected as a possible future adjuvant therapy to minimize cardiotoxic side effects of doxorubicin in cancer patients.

show abstract

“…These apparent unsuccessful studies also may be explained by variability between volunteers (age, body weight, nutrition, severity of diabetes) and/or duration of treatments [119]. In agreement with this hypothesis, another study of patients with metabolic syndrome treated the patients with 1500 mg/day of resveratrol for 90 days (~13 weeks) and revealed a significant reduction in body weight and insulin secretion [137]. Additionally, Goh et al [138] showed improvement of insulin sensitivity via SIRT1 through 3000 mg of resveratrol for 12 weeks in type-2 diabetic patients.…”

Section: Potential Of Natural Products With Antioxidant Effects Fomentioning

confidence: 97%

“…This is a problem because it has generated serious doubts about the potential usefulness of these substances, particularly for dietary prevention strategies [133,134,135,136]. For instance, Thazhath et al [137] have recently demonstrated that 1000 mg/day resveratrol in diet-controlled type-2 DM patients for five weeks did not change body weight, glycemic control or GLP-1 secretion. Similar data were also obtained by Poulsen et al [132], who gave 1500 mg/day of resveratrol for four weeks to obese patients and found no effects on metabolic biomarkers, blood pressure or resting energy expenditure.…”

Section: Potential Of Natural Products With Antioxidant Effects Fomentioning

confidence: 99%

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

Pereira

Pimenta

Porto

et al. 2016

IJMS

View full text Add to dashboard Cite

Because diabetes mellitus (DM) is a multifactorial metabolic disease, its prevention and treatment has been a constant challenge for basic and clinical investigators focused on translating their discoveries into clinical treatment of this complex disorder. In this review, we highlight recent experimental and clinical evidences of potential coadjuvants in the management of DM, such as polyphenols (quercetin, resveratrol and silymarin), cultured probiotic microorganisms and drugs acting through direct/indirect or pleiotropic effects on glycemic control in DM. Among several options, we highlight new promising therapeutic coadjuvants, including chemical scavengers, the probiotic kefir and the phosphodiesterase 5 inhibitors, which besides the reduction of hyperglycemia and ameliorate insulin resistance, they reduce oxidative stress and improve endothelial dysfunction in the systemic vascular circulation. In the near future, experimental studies are expected to clear the intracellular pathways involving coadjuvants. The design of clinical trials may also contribute to new strategies with coadjuvants against the harmful effects of diabetic complications.

show abstract

Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial

Cited by 105 publications

References 31 publications

Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants

Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants

Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

Contact Info

Product

Resources

About